



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):
A61K 9/00 ^(2006.01) **A61K 9/48** ^(2006.01)
A61K 31/198 ^(2006.01) **A61P 35/00** ^(2006.01)
A61P 35/02 ^(2006.01) **A61K 31/196** ^(2006.01)
A61K 47/10 ^(2017.01)

(48) Corrigendum issued on:
28.09.2022 Bulletin 2022/39

(52) Cooperative Patent Classification (CPC):
A61K 31/196; A61K 9/0019; A61K 9/4866;
A61K 31/198; A61K 47/10; A61P 35/00;
A61P 35/02

(45) Date of publication and mention
of the grant of the patent:
08.06.2022 Bulletin 2022/23

(21) Application number: **20179085.4**

(22) Date of filing: **13.04.2018**

(54) **(E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYL SULPHON
E FOR USE IN A METHOD OF TREATING CONDITIONS MEDIATED BY ABNORMAL CELL
PROLIFERATION**

**(E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYL SULPHON
E ZUR VERWENDUNG IN DER BEHANDLUNG VON ZUSTÄNDEN RESULTIEREND AUS
ABNORMALER ZELLPROLIFERATION**

**(E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYL SULPHON
E POUR L'UTILISATION POUR LE TRAITEMENT DES CONDITIONS QUI RESULTENT DE LA
PROLIFERATION CELLULAIRE ANORMALE**

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **13.04.2017 US 201762485355 P**
28.08.2017 US 201715688320
28.08.2017 PCT/US2017/048890

(43) Date of publication of application:
04.11.2020 Bulletin 2020/45

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
18718572.3 / 3 609 471

(73) Proprietor: **Onconova Therapeutics, Inc.**
Newtown, PA 18940 (US)

(72) Inventor: **MANIAR, Manoj**
Fremont, CA California 94539 (US)

(74) Representative: **V.O.**
P.O. Box 87930
2508 DH Den Haag (NL)

(56) References cited:
US-A1- 2015 313 859

• **RAZA AZRA ET AL: "Oral Rigosertib (ON
01910.Na) Treatment Produces A Encouraging
Rate Of Transfusion Independence In Lower Risk
Myelodysplastic Syndromes (MDS) Patients; A
Genomic Methylation Profile Is Associated With
Responses", BIOSIS, BIOSCIENCES
INFORMATION SERVICE, PHILADELPHIA, PA,
US, 1 November 2013 (2013-11-01), XP002788716,**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- NAVADA SHYAMALA C ET AL: "Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, 2 December 2016 (2016-12-02), XP002788717,
- NAVADA SHYAMALA C ET AL: "A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, 1 December 2015 (2015-12-01), XP002788718,
- RAMI S. KOMROKJI ET AL: "Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes", BRITISH JOURNAL OF HAEMATOLOGY, vol. 162, no. 4, 21 June 2013 (2013-06-21) , pages 517-524, XP055483608, GB ISSN: 0007-1048, DOI: 10.1111/bjh.12436